Drug Profile
Research programme: human monoclonal antibodies - Centocor/MorphoSys
Latest Information Update: 05 Mar 2008
Price :
$50
*
At a glance
- Originator Centocor; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 06 Jan 2005 MorphoSys and Centocor have extended their agreement until the end of 2007
- 26 Aug 2004 Centocor has extended its licence to the MorphoSys antibodies
- 15 Apr 2004 MorphoSys has achieved a fourth milestone in its cooperation with Centocor